tbuckley/cabot-search huggingface dataset:
Novel tumor suppressor gene loci on chromosomes 1p, 11q and 22q in insulinomas
Authors: Yvonne M H Jonkers, Sandra M H Claessen, Ton Feuth, Ad Geurts van Kessel, Frans C S Ramaekers, Joris A. Veltman, Ernst-Jan M. Speel
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

423 

Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with different clinical behavior and genetic constitution. Insulinomas represent the predominant syndromic subtype of EPTs. Our previous molecular studies have shown that gain of chromosome 9q is an important early event in tumor development, and that chromosomal instability is associated with metastatic disease (Endocrine-Related Cancer 2005, 12:435-447). In order to identify new gene loci and further narrow down previously detected regions of involvement, we investigated 27 insulinomas by array-based comparative genomic hybridization on 3.7 k genomic BAC arrays (resolution ≤ 1 Mb). Fluorescence in situ hybridization (FISH) was used to validate alterations in a subset of insulinomas. Along with previously identified alterations of large chromosomal regions, such as 9pq gain in 47% of the cases, several additional novel copy number changes encompassing relatively small genomic regions were identified. Loss of chromosome 1p36 (54%), 11q23.2-25 (43%) and 22q11-13.33 (44%) were most frequently detected. Amplification at chromosome 9q22 was found in one malignant insulinoma. In addition, genomic complexity was strongly increased with enhanced disease-state, as determined by the average number of chromosomal alterations present. Our study highlights novel locations of putative tumor suppressor gene loci that may contribute to the pathogenesis of insulinomas. Supported by the Netherlands Foundations Vanderes and Sacha Swarttouw-Hijmans, and the Association for International Cancer Research (AICR), St. Andrews, UK.
Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying <i>EGFR-</i>sensitizing mutations from the RADIANT trial.
Authors: Frances A. Shepherd, Nasser K. Altorki, Wilfried Ernst Erich Eberhardt, Mary E.R. O'Brien, David R. Spigel, Lucio Crino, Chun-Ming Tsai, Joo-Hang Kim, Eun Kyung Cho, Aleksandra Szczesna, Otto Burghuber, Philip C. Hoffman, Shaf Keshavjee, Sergey Orlov, Piotr Serwatowski, Jiuzhou Wang, Margaret A. Foley, Julie D. Horan, Frank C Richardson, Karen Kelly
Journal: Journal of Clinical Oncology (2014)

7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts with tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to EGFR TKIs. Methods: RADIANT was a randomized trial of postoperative E v P in pts with completely resected stage IB-IIIA NSCLC. Pts were stratified by histology (adenocarcinoma, other), stage (IB, II, IIIA), adjuvant chemotherapy (yes, no), smoking history (never, current/former), EGFR FISH (positive, negative/undetermined) and country. Pts were randomized 2:1 to receive E 150mg/day or P for up to 2 yr. Among 973 randomized pts, EGFR mutation status was determined for 921 (95%); 161 (17%) had mutations (55% exon 19 del, 45% exon 21 L858R). These pts form the basis of this report. Results: Pts with mutations were more frequently female (65%) and non-smokers (63%); 47% had stage IB, 29% stage II, 22% stage IIIA; 49% received adjuvant chemotherapy; 47% were Asian. Some imbalances were observed (E: less chemo and lower stage; P: smaller tumor size). There were 102 pts randomized to E and 59 to P. Median duration (range) of treatment was 21.2 (0.16-22.93) m for E and 21.9 (2.43-22.93) m for P; 34 (34%) and 24 (41%) pts completed >22 m of E and P, respectively. DFS events occurred in 71 (44%) pts. Pts on E had longer disease-free survival (DFS) v P (median 46.4 v 28.5 m; HR 0.61, 95% CI 0.38-0.98, p=0.039); however, this result is not statistically significant due to the hierarchical testing procedure. The effect on DFS remained consistent after adjusting for other prognostic variables via an exploratory multivariate Cox model (HR 0.60, 95% CI 0.36-0.98, p=0.046). There were more brain relapses on E (40%) v P (13%), and fewer bone relapses 14% v 29%. Deaths occurred in 35 (21.7%) pts. There was no significant difference in overall survival (OS median not reached in either arm; HR 1.09, 95% CI 0.56-2.16, p=0.815). For drug-related events, AE, serious AE and discontinuations for AE were higher with E compared to P (98% v 61%; 4% v 0%; 25% v 0%, respectively). Conclusions: Although not statistically significant, these data suggest adjuvant E prolongs DFS in pts with completely resected EGFR mutated NSCLC. OS interpretation is limited. Clinical trial information: NCT00373425.
Community-acquired rhinovirus infection is associated with changes in the airway microbiome
Authors: Kirsten M. Kloepfer, Vishal K. Sarsani, Valeriy Poroyko, Wai Ming Lee, Tressa E. Pappas, Theresa Kang, Kristine A. Grindle, Yury A. Bochkov, Sarath Chandra Janga, Robert F. Lemanske, James E. Gern
Journal: Journal of Allergy and Clinical Immunology (2017)
HCV Infection in Nongastric Marginal Zone B-Cell Lymphoma of MALT.
Authors: Luca Arcaini, Sara Burcheri, Andrea Rossi, Francesco Passamonti, Nora Colombo, Marco Paulli, Emanuela Boveri, Ercole Brusamolino, Alfredo Molteni, Alessandro Pulsoni, Maria Christina Cox, Lorella Orsucci, Alberto Fabbri, Maurizio Frezzato, Maria Teresa Voso, Francesco Zaja, Cristiana Pascutto, Enrica Morra, Sergio Cortelazzo, Mario Lazzarino
Journal: Blood (2005)
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
Authors: Rin Ogiya, Nobue Kumaki, Giampaolo Bianchini, Takayuki Iwamoto, Naoki Hayashi, Toshiya Tanaka, Naoki Niikura, Yutaka Tokuda
Journal: Journal of Clinical Oncology (2015)

11021 Background: The assessment of tumor-infiltrating lymphocytes (TILs) in primary breast cancer allow to predict prognosis and chemotherapy benefit, particularly in triple-negative (TN) and HER2-positive breast cancer. In the latter, it predicts also benefit from HER2-targeted agents. A little is known about the change of TILs during the metastatic progression. We compared TILs in paired samples from primary and metastatic TN and HER2-positive tumors. Methods: We retrospectively identified 25 patients with triple-negative or HER2-positive early breast cancer diagnosed between 1990 and 2010 at a single institution and subsequently experienced a distant recurrence confirmed by tumor biopsy/resection. Hematoxylin- and eosin-stained slides for these paired match cases were evaluated for stromal-TILs as recently recommended (Salgado R Ann Oncol 2014). We defined three groups according to : low-TILs ( ≤ 5), intermediate-TIL (10-50), Lymphocyte Predominant Breast Cancer (LPBC) ( ≥ 60%). Results: We evaluated 25 breast cancer patients (n = 11 TN; n = 14 HER2+). Primary tumors had 28% (LPBC), 52% (intermediate-TIL) and 20% (low-TIL). Corresponding first metastatic recurrences had 44% (intermediate-TIL) and 56% (low-TIL). Overall, TILs in primary tumors were significantly higher (average 34.6%) than at metastatic recurrences (average 15.7%) (paired t-test, p = 0.004). This difference was similar in HER2+ (p = 0.036) and TN (p = 0.06). In 13/25 (66%) cases the percentage of TILs decreased and in 3/25 increased (difference > 10%). We performed an exploratory analysis of post-progression overall-survival according to TIL at distant site of recurrence. The group with low-TIL had a significantly lower overall-survival than intermediate-TIL (HR = 3.77, CI 95% 0.99-14.9; logrank test p = 0.038). Conclusions: Tumor at first metastatic recurrence in TN and HER2+ breast cancer have lower infiltrating-lymphocytes compared to primary tumors, supporting a role for immune escape in tumor progression. Low-TIL at recurrences seemed to be associated with worst overall survival suggesting a more aggressive phenotype. These findings warrant independent confirmation.
PROGENITOR CELLS AND CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE
Authors: Ayman Samman Tahhan, Pratik Sandesara, Salim Hayek, Muhammad Hammadah, Marc Allard-Ratick, Bryan Kindya, Andreas Kalogeropoulos, Heval Mohamed Kelli, Matthew Topel, Ayman Alkhoder, Kaava Chivukula, Hiroshi Aida, Mohamad Mazen Gafeer, Eric Stahl, Heinl Robert, Naser Abdelhadi, Iraj Hesaroieh, Humza Naqvi, Ernestine Mahar, Jonathan Kim, Peter Wilson, Leslee Shaw, Viola Vaccarino, Edmund Waller, Arshed Quyyumi
Journal: Journal of the American College of Cardiology (2017)
Colitis endoscópica en pacientes tratados con ipilimumab. Un hallazgo excepcional
Authors: C Sánchez-Montes, MJ Quevedo, I Victoria, M Viladot, I Araujo, S Rodríguez-Tajes, P Llovet Laura, G Fernández-Esparrach, À Ginès, A Arance, J Llach
Journal: Endoscopy (2015)

Introducción: El melanoma avanzado es uno de los cánceres más agresivos. En los últimos años el tratamiento ha cambiado con el desarrollo del ipilimumab (anticuerpo monoclonal humano que bloquea el antígeno 4 del linfocito T citotóxico), mejorando la supervivencia de estos pacientes, aunque con posibles efectos adversos graves, como la afectación de la mucosa colónica.
Congenital Macrothrombocytopenia and Defective Localization of the Nonmuscle Myosin Heavy Chain IIA in Leukocytes and Megakaryocytes with a Normal MYH9 Gene.
Authors: Walter H. Kahr, Ling Li, Chanchai Traivaree, Hilary Christensen, Tara Paton, Sheila E. Butchard, Julie Curtin, Victor S. Blanchette
Journal: Blood (2004)
IMPROVEMENT OF LDL-CHOLESTEROL GOAL ATTAINMENT IN HIGH-RISK PATIENTS IN EUROPE AND MIDDLE EAST BETWEEN 2008-09 AND 2013-14: RESULTS OF DYSIS AND DYSIS II CHD
Authors: Anselm K. Gitt, Dominik Lautsch, Martin Horack, Philippe Brudi, Larry Liu, Jean Ferrières
Journal: Journal of the American College of Cardiology (2017)
A phase I, multicenter, open-label dosimetry study of I-131-CLR1404 in patients with relapsed or refractory advanced solid tumors who have failed standard therapy or for whom no standard therapy exists.
Authors: Joseph Chao, Joanne E. Mortimer, Steve Y. Cho, John Marshall, Terence Wong
Journal: Journal of Clinical Oncology (2012)

e13116 Background: I-131-CLR1404 is a small-molecule, iodophenyl-containing phospholipid ether analog that selectively delivers a cytotoxic beta-emitting radioisotope to cancer cells. In human tumor xenograft models, I-131-CLR1404 slowed malignant tumor growth and extended survival. Methods: A multi-center study evaluating total body and organ dosimetry, safety, and pharmacokinetics of 131-I-CLR1404 was conducted in 8 subjects with refractory solid tumors. We sought to determine the millicurie (mCi) dose of I-131-CLR1404 expected to deliver 35-40 centigray (cGy) to marrow, which will serve as the starting dose in a subsequent maximum tolerated dose (MTD) study. Subjects received a single dose of 10 mCi of I-131-CLR1404. Serial whole body planar scintigraphy images were obtained from 15 minutes to 6 days after I-131-CLR1404. Blood and urine samples were for biodistribution and pharmacokinetics. Results: Dosimetry calculations demonstrated consistency of organ and total body dosimetry in the 8 subjects. SPECT/CT images in a subset of patients indicated tumor-selective uptake of 131-I-CLR1404, showing a relative lack of uptake in adjacent normal tissue or bone marrow. No deaths or serious adverse events were reported during the study. A total of 7 subjects reported 19 AEs, 5 of which (all Grade 1) were considered by the investigator to be related to study medication. Based on the average red marrow dose of 0.56 mSv/MBq (2.09 rem/mCi), an administered activity of approximately 740 MBq (20 mCi will deliver 40 cGy (40 rem) to marrow, the starting dose in the Phase 1b (MTD) study. Conclusions: As a broad-spectrum, cancer-targeted molecular radiotherapeutic agent, I-131-CLR1404 may address at least two key limitations of current cancer therapies - lack of drug target expression and off-target toxicity. These results showan acceptable safety, dosimetry profile and selective uptake in malignant tumors. Further study of I-131-CLR1404 in cancer patients is warranted.
Management of venous thromboembolic events (VTE) in glioblastoma (GBM) patients: An ANOCEF (Association des Neuro-Oncologues d’Expression Française) Group study.
Authors: Emilie Le Rhun, Luc Taillandier, Francis Cajfinger, Lionel Vedrine, Dominique Farge, Patrick Devos, Sophie Taillibert
Journal: Journal of Clinical Oncology (2015)

e13008 Background: A 25% incidence rate of VTE is reported in GBM patients. The risk of intracranial bleeding under anticoagulation is the main concern. Methods: The ANOCEF has conducted a survey on VTE's management in GBM patients between 11.06.14 and 01.08.15. Results: 71 ANOCEF members have participated (24 neurosurgeons, 38 neuro-oncologists /oncologists, 9 radiation-oncologists). Participants answered handling directly these patients (49%), referring them to a VTE specialist (24%) or opting for one of these options according to the situation (21%). Only 31% confirmed to have access to a VTE multidisciplinary specialized team. In case of VTE without pulmonary embolism (PE), 50% and 38% declared respectively to prescribe low-molecular-weight-heparins (LMWH) alone or LMWH followed by anti-vitamin K (AVK) after 10 days. Anticoagulation's duration is variable : 3 (42%) or 6 (15%) months otherwise same duration than the anticancer treatment (36%). Compression stockings are added by 79% of participants. In case of PE, anticoagulation lasts 3 (14%) or 6 (41%) months otherwise same duration than the anticancer treatment (41%). Thrombopenia is the main cause of anticoagulants'interruption: mostly when platelets are < 100 000 /mm3 (25%) or < 50 000 /mm3 (55%). Bevacizumab is interrupted for 2 weeks or less or until TVP/PE resolution by 18% and 14% of participants, respectively. Bevacizumab is definitively stopped in case of bilateral massive PE only by 18% of participants. A veina cava filter (VCF) is sometime prescribed by 55% of participants, mostly when anticoagulants are contra-indicated (46%) and in case of symptomatic intracranial bleeding (42%). After tumor biopsies or resections, a prophylactic anticoagulation is administered respectively until the patient's discharge (39%/11%), during 1 month (11%/20%) and according to the risk factors (36%/31%). Conclusions: This study shows a great heterogeneity in the management of VTE in glioblastoma patients in France. National guidelines are needed. Once validated, repeating this survey may check their implementation.
A survey on Japanese thoracic oncologists’ preference on treatment strategy for EGFR-mutant or EML4-ALK-mutant non-small cell lung cancer (NSCLC).
Authors: Katsuyuki Hotta, Katsuyuki Kiura, Masarhiro Tabata, Nagio Takigawa, Mitsune Tanimoto, Hiroshi Ueoka
Journal: Journal of Clinical Oncology (2013)

e19124 Background: NSCLC pts have become categorized based on two genetic alterations in their tumors, EGFR and EML4-ALK, to provide personalized therapy. In EGFR-mutant NSCLC, EGFR-TKI yields a comparable survival with platinum-based chemotherapy, suggesting either of them can be initiated first, and its choice seems to depend partly on oncologists’ preference. As for the other, EML4-ALK, NCCN guideline recommends first-line crizotinib use despite no relevant survival data. The decision whether to choose crizotinib might be also influenced by oncologists’ preference. We here assessed their preference. Methods: The Japanese thoracic oncologists were asked to complete a self-administered questionnaire at the Japanese meeting specific for thoracic oncology. Results: Of 3,046 subjects, 871 (29%) responded voluntarily to a survey, mainly consisting of medical and surgical oncologists (93%). Majority considered EGFR mutation status should be checked at the time of diagnosis (89%), whereas only 60% and 33% reported EML4-ALK gene status would be assessed at the time of diagnosis and until the initiation of second-line setting, respectively. The subjects also considered pts with EGFR-wild-typed tumor and pts with clinical characteristics possibly related to EML4-ALK rearrangement should selectively receive EML4-ALK gene status check rather than all NSCLC pts (57%, 22% and 16%, respectively). Among the subjects, 52% preferred to choose gefitinib rather than platinum in the first-line setting in EGFR-mutant NSCLC, whilst 44% preferred crizotinib to platinum in the first-line setting in EML4-ALK-positive NSCLC. The major reasons why they chose gefitinib in EGFR-mutant NSCLC were ‘PFS is better’ (36%) and ‘it is easy to improve QOL’ (25%), whereas ‘PFS is better’ (43%), and ‘I want to prescribe when patients are still in good condition’ (19%) were the predominant reasons for choosing crizotinib in EML4-ALK-positive NSCLC. Conclusions: About half of the subjects preferred each molecular-targeted agent to the conventional cytotoxic chemotherapy in first-line setting. They considered better PFS was important in the treatment of EGFR-mutant or EML4-ALK-mutant NSCLC.
EFFECTS OF SUCCESSFUL PERCUTANEOUS CORONARY INTERVENTION OF CHRONIC TOTAL OCCLUSIONS ON MYOCARDIAL PERFUSION AND LEFT VENTRICULAR FUNCTION
Authors: Stefan Schumacher, Wijnand Stuijfzand, Paul Biesbroek, Pieter Raijmakers, Roel Driessen, Pepijn van Diemen, Jeffrey van den Berg, Robin Nijveldt, Adriaan Lammertsma, Simon Walsh, Colm G. Hanratty, James Spratt, Albert C. van Rossum, Alexander Nap, Niels Van Royen, Paul Knaapen
Journal: Journal of the American College of Cardiology (2017)
Dual endothelin-1/VEGFsp receptor (DEspR): Common target on tumor vascular endothelial cells (TVECs), tumor cells (TCs), and cancer stem cells (CSCs) in glioblastoma and pancreatic cancer.
Authors: Victoria L.M. Herrera, Glaiza L.A. Tan, Ann Marie Moran, Kristine A. Pasion, Julius L Decano, Nelson Ruiz-Opazo
Journal: Journal of Clinical Oncology (2012)

e13574 Background: New therapies are needed for glioblastoma (GBM) and pancreatic adenocarcinoma (PCa), given their low survival rates. To address this mandate, we tested the hypothesis that inhibition of DEspR, as a common target on TVECs, TCs, and CSCs, can affect multiple key steps in metastasis: angiogenesis, invasiveness, anoikis resistance. Methods: Various analyses were performed: co-immunostaining of tumor tissue and cancer cell lines from PCa and GBM using anti-CD133 and anti-DEspR mAbs; in vitro anti-DEspR mAb inhibition of angiogenesis and TC invasiveness; isolation, functional validation, and DEspR immunostaining of CSCs from PCa (Panc1) and GBM (U87) cell lines; DEspR inhibition of Panc1- and U87-derived CSC tumorsphere formation and CSC-enriched xenograft tumor growth in nude rats respectively; and phosphoproteome analysis of DEspR signaling. Results: In PCa and GBM, we detected DEspR+ TVECs, TCs, and CD133+ putative CSCs in contrast to respective normal tissues. DEspR expression on TCs and TVECs were confirmed in PCa (Panc1) and GBM (U87) cell lines, and HUVECs undergoing angiogenesis, respectively. Dose-dependent anti-DEspR mAb inhibition decreased HUVEC angiogenesis and Panc1 invasiveness compared to isotype controls. DEspR+ expression was detected in functionally validated Panc1 and U87 CSCs exhibiting tumorsphere formation, increased tumorigenicity in nude rat xenograft models, and self-renewal from xenograft tumors. DEspR inhibition decreased tumorsphere formation and increased dead cell numbers, suggesting decreased anoikis resistance for both U87 and Panc1 CSCs. Phosphoproteome analysis detected DEspR signaling through phosphoproteins implicated in TVEC-TC crosstalk, angiogenesis, and anoikis resistance. DEspR inhibition decreased tumor growth of Panc1 and U87 CSC-enriched subcutaneous xenograft tumors in nude rat models. Conclusions: Data demonstrate DEspR as a common target on TVECs, TCs, and CSCs in PCa and GBM, whose inhibition provides a potential therapeutic strategy for simultaneous inhibition of multiple pro-malignancy steps: angiogenesis, invasiveness, and anoikis resistance.
BURDEN OF 30-DAY READMISSIONS IN ACUTE MYOCARDIAL INFARCTION AND HEART FAILURE IN THE UNITED STATES: A NATIONAL PERSPECTIVE
Authors: Rohan Khera, Saket Girotra, Ambarish Pandey, Snigdha Jain, Colby Ayers, Sandeep Das, Jarett Berry, James A. de Lemos, Gregg Fonarow
Journal: Journal of the American College of Cardiology (2017)
Prognostic factors in metastatic gastric cancer patients (pts) treated with second-line chemotherapy
Authors: V. Catalano, F. Graziano, D. Santini, A. M. Baldelli, P. Giordani, B. Vincenzi, D. Rossi, P. Alessandroni, G. Tonini, G. Catalano
Journal: Journal of Clinical Oncology (2007)

15169 Background: Currently, there is no established second-line chemotherapy for pts with advanced gastric cancer who failed to respond or progressed after a first-line chemotherapy. Many of these pts still have a good performance status or have symptoms to be palliated at the time of first-line failure and are candidates for second-line chemotherapy. However, phase II trials demonstrate divergent results about pts more likely to benefit from second-line chemotherapy. We retrospectively analyzed the influence of various clinicopathologic factors on the survival of pts treated with second-line chemotherapy. Methods: Analysis is based on the data of 169 pts consecutively treated at 3 oncology department with a second-line chemotherapy. Univariate and multivariate analyses were performed to determine prognostic factors of survival. The variable used for analysis were: sex, age, ECOG performance status, a weight loss &gt; 5 Kg in the last month; site of primary tumor, histopathology; hemoglobin, serum albumin, and CEA levels, number and site of metastatic disease, response to and time-to-progression (TTP) with the first- line chemotherapy. Results: The variables predictive of better survival were: ECOG PS 0–1 (p&lt;0.001), no weight loss (p=0.001), hemoglobin level &gt; 10 g/dl (p=0.01), CEA level &lt;50 U/ml (p&lt;0.02), number of metastatic sites = 2 (p=0.002), TTP of the first-line chemotherapy &gt; 4 months (p=0.008). Peritoneal carcinomatosis was predictive of poor survival only when associated with one or more signs or symptoms as vomiting, anorexia, abdominal pain, ascites(p=0.03). Four factors were independently associated with better overall survival: ECOG PS 0–1 (p=0.002; HR 0.46; CI 95%, 0.29–0.75), CEA level &lt;50 U/ml (p=0.008; HR 0.54; CI 95%, 0.35–0.85), one or two metastatic sites of disease (p=0.01; HR 0.58; CI 95%, 0.39–0.88), and TTP of the first-line chemotherapy &gt; 4 months (p=0.02; HR 0.66; CI 95%, 0.45–0.95). Conclusions: In the absence of data deriving from randomized, controlled, clinical trials, this analysis suggests that some clinical factors may help clinicians to better select groups of pts with gastric cancer more likely to benefit from a second-line chemotherapy. No significant financial relationships to disclose.
Transfusion Dependence in Patients with Primary Myelofibrosis Has a Negative Impact on Survival Independent of Decreased Myelopoiesis.
Authors: Heather A. Leitch, Hatoon Ezzat, Meaghan D. Rollins, Dominic H.C. Wong, Chantal S. Leger, Khaled M. Ramadan, Michael J. Barnett, Linda M. Vickars
Journal: Blood (2007)
WHAT ARE THE DIFFERENCES IN ORAL ANTICOAGULANT TREATMENT PERSISTENCE IN NON-VALVULAR ATRIAL FIBRILLATION IN EUROPE? REAL-WORLD STUDIES IN THREE EUROPEAN COUNTRIES
Authors: Laurent Fauchier, Shuk-Li Collings, Michelle Johnson, Gillian Stynes, David Evans, Virginie Vannier-Moreau, Guido Hack, Matthew Lumley, Andrew Maguire, Cinira Lefevre, Bristol-Myers Squibb
Journal: Journal of the American College of Cardiology (2017)
PULMONARY VASCULAR RESISTANCE, BUT NOT DIASTOLIC PULMONARY GRADIENT, MAY PREDICT SURVIVAL IN PULMONARY HYPERTENSION: INSIGHTS FROM EUPHRATES STUDY
Authors: Cihangir Kaymaz, Ozgur Akbal, Fatih Yilmaz, Hacer Ceren Tokgoz, Ibrahim Halil Tanboga, Aykun Hakgor, Canan Elif Yildiz, Sevim Turkday, Nertila Poci, Tugba Aktemur, Durmus Demir, Seda Tanyeri, Nihal Ozdemir
Journal: Journal of the American College of Cardiology (2017)
Altered Erythroid and Megakaryocytic Differentiation in Mice Expressing a Unique Chromatin Remodeling Domain of Erythroid Krüppel-Like Factor (EKLF)
Authors: Valerie M. Jansen, Tatiana Abramova, Eun-Hee Shim, Shaji Ramachandran, Aurelie Desgardin, Vishwas Parekh, Stephen Jane, John M Cunningham
Journal: Blood (2008)